Literature DB >> 950801

Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide.

J V Donadio, K E Holley, R H Ferguson, D M Ilstrup.   

Abstract

We report a prospective randomized study of 39 patients with systemic lupus erythematosus and progressive glomerulonephritis who were assigned to treatment groups that received either prednisone alone or prednisone and cyclophosphamide combined. They received treatment for 6 months and were then followed up for an additional 18 months. No difference in outcome was seen in the two groups at the end of 6 months. Among patients followed up for an average of 24 months, fewer individuals showed later renal progression among those treated with cyclophosphamide and prednisone than among the group treated with prednisone alone.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950801

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

Review 1.  Combination treatment in autoimmune diseases: systemic lupus erythematosus.

Authors:  G Moroni; O Della Casa Alberighi; C Ponticelli
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Clinical trials in lupus nephritis.

Authors:  E M Ginzler
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 3.  Treatment of severe proliferative lupus nephritis: the current state.

Authors:  C C Mok; R W S Wong; K N Lai
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 4.  Therapeutic aspects. Immunosuppression in established humoral responses.

Authors:  R F Gagnon; I C MacLennan
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

5.  The treatment of the nephritis of lupus erythematosus.

Authors: 
Journal:  West J Med       Date:  1977-06

6.  The effect of chronic daily cyclophosphamide administration on established antibody responses.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Regulation of secondary antibody responses in rodents. I. Potentiation of IgG production by cyclophosphamide.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

8.  Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases.

Authors:  P Hollingworth; A de Vere Tyndall; B M Ansell; T Platts-Mills; J M Gumpel; J Mertin; D S Smith; A M Denman
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

Review 9.  Immunosuppressive treatment for proliferative lupus nephritis.

Authors:  David J Tunnicliffe; Suetonia C Palmer; Lorna Henderson; Philip Masson; Jonathan C Craig; Allison Tong; Davinder Singh-Grewal; Robert S Flanc; Matthew A Roberts; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2018-06-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.